Results 191 to 200 of about 424,438 (249)

Health economic evaluation of Mirvetuximab soravtansine for the treatment of FRα-positive, platinum resistant ovarian cancer in Germany. [PDF]

J Cancer Res Clin Oncol
Janke FF, Baldessarini RJ, Bauerschlag D, Zibolka S, Hartmann M.   +4 more
europepmc   +1 more source

Patient out-of-pocket costs and rheumatology biosimilar competition. [PDF]

J Manag Care Spec Pharm
Dayer VW, Hansen RN, Roth J, Jofre-Bonet M, Sullivan SD.   +4 more
europepmc   +1 more source

Economic evaluation of alternative hepatitis C treatment options: a post hoc analysis of the VIETNARMS trial. [PDF]

EClinicalMedicine
Turner HC, Ahmed S, Nguyen HA, Hung LM, Van Nuil J, Thuan DT, SEARCH investigators, Dung NT, Thwaites GE, Walker AS, Chau NVV, Cooke GS, Hallett TB.   +12 more
europepmc   +1 more source

GENERATIVE AI TOWARDS A COMPARATIVE ANALYSIS OF HOSPITALIZATION RATES AMONG PATIENTS WITH ULCERATIVE COLITIS TREATED WITH INFLIXIMAB, VEDOLIZUMAB, AND TOFACITINIB IN THE PUBLIC HEALTHCARE SYSTEM IN BRAZIL: A NATIONWIDE STUDY. [PDF]

Arq Gastroenterol
Valverde DA, Quaresma AB, Villamil MPG, Moraes TP, Kotze PG.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The Cost of Drug Development

New England Journal of Medicine, 2015
The Tufts Center for the Study of Drug Development designed the recent study of the costs of new drug research and development to capture only the costs incurred by industry, but typically R&D efforts in the private and public sectors are complements, not substitutes.
DiMasi, Joseph A, Grabowski, Henry G, Hansen, Ronald W   +2 more
openaire   +2 more sources